KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Cost of Revenue (2016 - 2025)

Fulgent Genetics' Cost of Revenue history spans 11 years, with the latest figure at $50.8 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 14.4% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $191.8 million, up 8.82%, while the annual FY2025 figure was $191.8 million, 8.82% up from the prior year.
  • Cost of Revenue for Q4 2025 was $50.8 million at Fulgent Genetics, down from $120.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $223.4 million in Q4 2022 and bottomed at $7.9 million in Q1 2022.
  • The 5-year median for Cost of Revenue is $39.7 million (2021), against an average of $47.3 million.
  • The largest annual shift saw Cost of Revenue surged 4538.38% in 2021 before it crashed 89.28% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $62.1 million in 2021, then skyrocketed by 259.55% to $223.4 million in 2022, then crashed by 79.73% to $45.3 million in 2023, then decreased by 2.01% to $44.4 million in 2024, then rose by 14.4% to $50.8 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Cost of Revenue are $50.8 million (Q4 2025), $120.3 million (Q3 2025), and $12.3 million (Q2 2025).